These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 1808341)

  • 41. [Paracalcitiol compared with calcitriol in treatment of secondary hyperparathyroidism in patients with hemodyalisis. Are they really different?].
    Peña-Rodriguez JC
    Rev Invest Clin; 2004; 56(1):8-10. PubMed ID: 15144035
    [No Abstract]   [Full Text] [Related]  

  • 42. Are calcitriol boli worth the return to aluminum hydroxide as a phosphate binder in severe secondary hyperparathyroidism?
    Calabrese G; Vagelli G; Gonella M
    Nephron; 1995; 71(1):113-4. PubMed ID: 8538836
    [No Abstract]   [Full Text] [Related]  

  • 43. Novel, selective vitamin D analog suppresses parathyroid hormone in uremic animals and postmenopausal women.
    Zella JB; Plum LA; Plowchalk DR; Potochoiba M; Clagett-Dame M; DeLuca HF
    Am J Nephrol; 2014; 39(6):476-83. PubMed ID: 24854296
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Osteopenia during long-term haemodialysis: response to vitamin D3 analogues.
    Muirhead N; Adami S; Fraser RA; Catto GR; Edward N; O'Riordan JL
    Proc Eur Dial Transplant Assoc; 1981; 18():567-72. PubMed ID: 6895786
    [No Abstract]   [Full Text] [Related]  

  • 45. Does it matter how parathyroid hormone levels are suppressed in secondary hyperparathyroidism?
    Stubbs JR; Wetmore JB
    Semin Dial; 2011; 24(3):298-306. PubMed ID: 21682772
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Which is the preferred treatment of advanced hyperparathyroidism in a renal patient? I. Medical intervention is the primary option in the treatment of advanced hyperparathyroidism in chronic renal failure.
    Gallieni M; Brancaccio D
    Nephrol Dial Transplant; 1994; 9(12):1816-9. PubMed ID: 7708274
    [No Abstract]   [Full Text] [Related]  

  • 47. The effect of calcitriol on renal anaemia in patients undergoing long-term dialysis.
    Nazem AK; Makó J
    Int Urol Nephrol; 1997; 29(1):119-27. PubMed ID: 9203048
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The use of 1,25-dihydroxyvitamin D3 in early renal failure.
    Goodman WG; Coburn JW
    Annu Rev Med; 1992; 43():227-37. PubMed ID: 1580587
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hyperparathyroidism in CAPD patients: therapy with pulse oral calcitriol.
    Juergensen PH; Finkelstein FO; Cooper K; Santacroce S; Kliger AS
    Adv Perit Dial; 1993; 9():257-9. PubMed ID: 8105938
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy and tolerability of intravenous paricalcitol in calcitriol-resistant hemodialysis patients with secondary hyperparathyroidism: 12-month prospective study.
    Tonbul HZ; Solak Y; Atalay H; Turkmen K; Altintepe L
    Ren Fail; 2012; 34(3):297-303. PubMed ID: 22251408
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Pharmacological action and clinical effects of falecalcitriol, a highly potent derivative of active vitamin D3].
    Ohtsuka N; Urayama K
    Nihon Yakurigaku Zasshi; 2002 Dec; 120(6):427-36. PubMed ID: 12528474
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The approach to the treatment of secondary hyperparathyroidism in early renal failure.
    Fournier A; Morinière P; Renaud H
    Am J Nephrol; 1988; 8(2):170-2. PubMed ID: 3394724
    [No Abstract]   [Full Text] [Related]  

  • 53. Vitamin D therapy in children on dialysis.
    Wesseling K; Salusky IB
    Perit Dial Int; 2007; 27(6):651-3. PubMed ID: 17984426
    [No Abstract]   [Full Text] [Related]  

  • 54. Recent progress in management of secondary hyperparathyroidism of chronic renal failure.
    Akizawa T; Fukagawa M; Koshikawa S; Kurokawa K
    Curr Opin Nephrol Hypertens; 1993 Jul; 2(4):558-65. PubMed ID: 7859018
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Oral manifestations of secondary hyperparathyroidism related to long-term hemodialysis therapy.
    Fletcher PD; Scopp IW; Hersh RA
    Oral Surg Oral Med Oral Pathol; 1977 Feb; 43(2):218-26. PubMed ID: 401975
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mode of progression of secondary hyperparathyroidism in patients with chronic renal failure.
    Matsubara M; Sugai H; Taguma Y; Ishizaki M; Suzuki K; Takahashi H; Saito T; Yoshinaga K
    Nephron; 1991; 58(1):122-3. PubMed ID: 1857473
    [No Abstract]   [Full Text] [Related]  

  • 57. [Abnormalities in parathyroid hormone and calcitonin associated with uremia].
    Okazaki R
    Nihon Rinsho; 2004 Jun; 62 Suppl 6():169-72. PubMed ID: 15250289
    [No Abstract]   [Full Text] [Related]  

  • 58. 1,25 (OH)2 vitamin D3 deficiency and renal osteodystrophy: should its well-accepted pathogenetic role in secondary hyperparathyroidism lead to its systematic preventive therapeutic use?
    Fournier A; Moriniere P; Boudaillez B; Renaud H; Marie A; Westeel PF; Hocine C; Belbrik S
    Nephrol Dial Transplant; 1987; 2(6):498-503. PubMed ID: 3126450
    [No Abstract]   [Full Text] [Related]  

  • 59. No change in circulating osteoprotegerin levels by intravenous calcitriol therapy among dialysis patients with secondary hyperparathyroidism.
    Nishi H; Nii-Kono T; Ikeda K; Fujimori A; Fukagawa M
    Clin Nephrol; 2006 Feb; 65(2):149-50. PubMed ID: 16509469
    [No Abstract]   [Full Text] [Related]  

  • 60. Effects of 1,25-dihydroxy vitamin D3 in patients with early renal failure.
    Lam M; Llach F
    Adv Exp Med Biol; 1982; 151():361-73. PubMed ID: 6897482
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.